In addition, YTHDF2 is positively regulated by the EGFR/SRC/ERK pathway and facilitates the malignancy progression of GBM by degrading downstream transcripts, including LXRα, HIVEP2, UBXN1, and ASS1 mRNAs in an m6A-dependent manner (43, 278, 279). The gene discussed is YTHDF2; the disease is glioblastoma.